Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies.

Autor: Amaldoss MJN; Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia; School of Materials Science and Engineering, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: dr.mariajohnnewton@gmail.com., Yang JL; Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia., Koshy P; School of Materials Science and Engineering, UNSW Sydney, Sydney, NSW 2052, Australia., Unnikrishnan A; Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia., Sorrell CC; School of Materials Science and Engineering, UNSW Sydney, Sydney, NSW 2052, Australia.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2022 Dec; Vol. 27 (12), pp. 103386. Date of Electronic Publication: 2022 Sep 29.
DOI: 10.1016/j.drudis.2022.103386
Abstrakt: Inorganic nanoparticles for drug delivery in cancer treatment offer many potential advantages because they can maximize therapeutic effect through targeting ligands while minimizing off-target side-effects through drug adsorption and infiltration. Although inorganic nanoparticles were introduced as drug carriers, they have emerged as having the capacity for combined therapeutic capabilities, including anticancer effects through cytotoxicity, suppression of oncogenes and cancer cell signaling pathway inhibition. The most promising advanced strategies for cancer therapy are as synergistic platforms for RNA interference (siRNA, miRNA, shRNA) and as synergistic drug delivery agents for the inhibition of cancer cell signaling pathways. The present work summarizes relevant current work, the promise of which is suggested by a projected compound annual growth rate of ∼ 20% for drug delivery alone.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: